Oxcarbazepine

Generic Name: Oxcarbazepine

Brand Names: Oxtellar, Trileptal

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₂N_₂O_₂

CAS Number: 28721-07-5

Unique Ingredient Identifier: VZI5B1W380

Background: Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active...

Indication: In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
...

Associated Conditions: Partial-Onset Seizures

Associated Therapies: Monotherapy

Clinical Trials

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: Morphine
Drug: Oxcarbazepine

First Posted Date: 2014-03-05

Last Posted Date: 2017-01-31

Lead Sponsor: Costantine Albany

Target Recruit Count: 1

Registration Number: NCT02078089

Locations: 🇺🇸
Indiana Univeristy Health Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

Phase 4

Conditions: Bipolar Disorder

Interventions: Drug: Ziprasidone
Drug: Valproate
Drug: Lithium
Drug: Oxcarbazepine
Drug: Quetiapine
Drug: Olanzapine

First Posted Date: 2013-07-08

Last Posted Date: 2015-03-17

Lead Sponsor: Guiyun Xu

Target Recruit Count: 120

Registration Number: NCT01893229

Locations: 🇨🇳
Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China

Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)

Phase 3

Terminated

Conditions: Epilepsy, Partial
Epilepsy, Localization Related

Interventions: Drug: Levetiracetam
Drug: Lamotrigine
Drug: Oxcarbazepine

First Posted Date: 2013-07-03

Last Posted Date: 2017-09-19

Lead Sponsor: Emory University

Target Recruit Count: 72

Registration Number: NCT01891890

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States

and more 11 locations

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Oxcarbazepine

First Posted Date: 2012-10-10

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 59

Registration Number: NCT01703468

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Oxcarbazepine

First Posted Date: 2012-10-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 64

Registration Number: NCT01702623

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Oxcarbazepine

First Posted Date: 2012-09-05

Last Posted Date: 2015-01-08

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 13

Registration Number: NCT01678976

Locations: 🇵🇹
BIAL - Portela & Cª - Human Pharmacology Unit (UFH), S. Mamede do Coronado, Trofa, Portugal

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: BIA 2-093
Drug: Oxcarbazepine

First Posted Date: 2012-09-05

Last Posted Date: 2015-01-01

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 12

Registration Number: NCT01679002

Locations: 🇵🇹
BIAL - Portela & Cª S.A. - Human Pharmacology Unit (UFH), S. Mamede do Coronado, Trofa, Portugal

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Levetiracetam
Drug: Oxcarbazepine

First Posted Date: 2011-12-23

Last Posted Date: 2015-08-20

Lead Sponsor: Korea UCB Co., Ltd.

Target Recruit Count: 353

Registration Number: NCT01498822

Locations: 🇰🇷
05, Busan, Korea, Republic of
🇰🇷
10, Busan, Korea, Republic of
🇰🇷
16, Busan, Korea, Republic of

and more 20 locations

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain

Phase 4

Completed

Conditions: Polyneuropathy
Peripheral Nerve Injury
Postherpetic Neuralgia

Interventions: Drug: Oxcarbazepine

First Posted Date: 2011-02-24

Last Posted Date: 2014-05-05

Lead Sponsor: Søren H. Sindrup

Target Recruit Count: 117

Registration Number: NCT01302275

Locations: 🇩🇰
Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Department of Neurology, Odense University Hospital, Odense, Denmark

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Phase 2

Completed

Conditions: Partial Onset Seizures

Interventions: Drug: Oxcarbazepine

First Posted Date: 2010-01-18

Last Posted Date: 2019-11-15

Lead Sponsor: Nobelpharma

Target Recruit Count: 88

Registration Number: NCT01051193

Locations: 🇯🇵
NPC Investigative Site, Yamagata, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy